Novartis' Arogya Parivar initiative is a pioneering business approach which aims to deliver healthcare sustainably to more people, particularly in the developing world.
Novartis is proud to have achieved Silver Class status in this year’s edition of the RobecoSAM “Sustainability Yearbook” for our excellent sustainability performance.
When endocrinologist Ann Taylor was working at Massachusetts General Hospital, she met a woman with McCune-Albright syndrome, a rare disorder that affects the skin, bones and several hormone-producing tissues.
Parents and doctors can help children understand rare diseases like TSC and SJIA with the help of cartoon dogs and comic book superheroes.
After 40 years of working in information technology, Jim Barrington took a partial retirement from his job as Novartis’ chief information officer and started looking for new ways to apply his skills.
Novartis has joined forces with lymphoma experts in academia to hack into the genetics of a rare form of blood cancer known as mantle cell lymphoma (MCL).
With extensive experience in public health management, having worked for the International Red Cross, among others, and as a doctor in emergency situations on the ground in Africa and Asia— Ann Aerts discusses the Novartis Foundation's new leprosy strategy.
Inclusion in the 2014 index acknowledges Novartis leadership in key areas of corporate responsibility. Companies named to the Global 100 are recognized as the top overall sustainability performers in their respective industries.
When the average person thinks of cancer research, one word is likely to spring to mind: cure. Almost everyone who has ever lost a friend or loved one to the disease is hoping for a permanent, reliable cure for cancer. The sooner, the better.
Review the strategy and annual performance of Novartis and read letters from our Chairman and CEO.
This site is intended for a global audience.